Smith out as Angeion CEO

Angeion, which develops and markets devices to treat irregular heartbeats, has announced that Philip Smith has resigned as the company's CEO. The decision was a mutual one between Smith and the company's board of directors. Smith became president and CEO of the company effective January 1, 2011 pursuant to a letter agreement that provided for at-will employment. Gregg Lehman will serve as interim CEO, effective immediately. Angeion release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.